OPK
Opko Health, Inc.
A Miami-based healthcare company that pairs one of the largest clinical reference laboratories in the United States with drug development, Opko Health makes the 4Kscore blood test, which gauges a man's risk of aggressive prostate cancer, and the kidney-disease treatment Rayaldee. It took shape in 2007 when biotech investor Phillip Frost merged three firms—Acuity Pharmaceuticals, Froptix, and eXegenics—into today's company. The name OPKO has no hidden meaning; it's simply a made-up brand Frost chose for the venture.
CUSIP: 68375N103HealthcareUS1 holder
Total Value
$40.0K
Total Shares
10.0K
Net Share Change
+10.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
